MedPath

Role of Inflammatory markers in different grades of Diabetic Foot Ulcer

Not Applicable
Conditions
Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
Registration Number
CTRI/2023/07/055588
Lead Sponsor
Dr Shaheen B Shaikh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

A total of 125 diabetic foot ulcer patients and 125 diabetic patients without foot ulcer (free from foot wounds and acute or chronic disease), admitted to surgery wards will be enrolled in the study. All wounds will be graded when they will get admitted to the hospital according to the Wagner classification system into five grades (grade I - grade V), the number of patients in each group will be 25.Foot ulcer was defined as a full-thickness skin defect that required >=14 days for healing. Cases and controls will be matched for age (±3 years), sex and duration of Diabetes.

Exclusion Criteria

Patients with inflammatory or infectious diseases, autoimmune

and rheumatic diseases, cancer, hematological diseases, malignancy, Pregnancy ,lactation ,Chronic inflammatory disorders, severe renal or liver failure, recent venous thromboembolism ,as well as those who were under treatment with immunodeficiency drugs , will be excluded from study . Foot ulcers caused by other conditions such as arterial insufficiency, venous insufficiency, or trauma will be excluded

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
the study may provide new insights that could lead to better diagnosis, prevention, & treatment of this condition, ultimately improving the health outcomes & well-being of affected individuals.Timepoint: At Baseline, 4 weeks and 8 weeks
Secondary Outcome Measures
NameTimeMethod
This study can also raise the possibility that inflammatory markers might provide an adjunctive method for early detection of risk for this disease & ultimately decreases the lower limb amputation & hence decreasing the mortality & morbidity of patients with DFU.Timepoint: At Baseline, 4 weeks & 8 weeks
© Copyright 2025. All Rights Reserved by MedPath